




RealRate

PHARMACEUTICAL 2020

Endonovo Therapeutics INC
Rank 349 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Endonovo Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Endonovo Therapeutics INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 11% points. The greatest weakness of Endonovo Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 161% points.

The company's Economic Capital Ratio, given in the ranking table, is 26%, being 212% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	63
Cost of Goods Sold	93
Intangible Assets	3,206
Liabilities, Current	23,623
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	4,026
Other Liabilities	155
Other Net Income	-13,505
Other Revenues	310
Property and Equipment	5.9
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	3,275
Liabilities	23,778
Expenses	4,119
Revenues	310
Stockholders Equity	-20,504
Net Income	-17,315
Comprehensive Net Income	-17,315
BaseVar	22,494
ECR before LimitedLiability	-458%
Economic Capital Ratio	26%